Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
six
months ended in Sep. 2025,
Sai Parenteral's received₹1,052 Mil more from issuing new shares than it paid to buy back shares.
It spent₹179 Mil paying down its debt.
It paid₹0 Mil more to buy back preferred shares than it received from issuing preferred shares.
It received₹0 Mil from paying cash dividends to shareholders.
It spent₹32 Mil on other financial activities.
In all, Sai Parenteral'searned₹841 Mil on financial activities for the
six
months ended in Sep. 2025.
Sai Parenteral's (NSE:SAIPARENT) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Sai Parenteral's's issuance of stock for the
six
months ended in Sep. 2025 was ₹1,052 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Sai Parenteral's's repurchase of stock for the
six
months ended in Sep. 2025 was ₹0 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Sai Parenteral's's net issuance of debt for the
six
months ended in Sep. 2025 was ₹-179 Mil.
Sai Parenteral's spent₹179 Mil paying down its debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Sai Parenteral's's net issuance of preferred for the
six
months ended in Sep. 2025 was ₹0 Mil.
Sai Parenteral's paid₹0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Sai Parenteral's's cash flow for dividends for the
six
months ended in Sep. 2025 was ₹0 Mil.
Sai Parenteral's received₹0 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Sai Parenteral's's other financing for the
six
months ended in Sep. 2025 was ₹-32 Mil.
Sai Parenteral's spent₹32 Mil on other financial activities.
Sai Parenteral's Cash Flow from Financing Related Terms
Sai Parenteral's Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for Sai Parenteral's's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sai Parenteral's Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Sai Parenteral's's Cash from Financing for the fiscal year that ended in Mar. 2025 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Sep. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹841 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of ₹841 Mil mean?
Sai Parenteral's (NSE:SAIPARENT) has a Cash Flow from Financing of ₹841 Mil as of Sep. 2025. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Sai Parenteral's and its competitors.
Is Sai Parenteral's' Cash Flow from Financing too high?
Sai Parenteral's' current Cash Flow from Financing is ₹841 Mil. Overall, Sai Parenteral's has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Sai Parenteral's' Cash Flow from Financing compare to LLY and JNJ?
Sai Parenteral's' Cash Flow from Financing of ₹841 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Drug Manufacturers company?
A good Cash Flow from Financing depends on the Drug Manufacturers industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Sai Parenteral's and its competitors. Sai Parenteral's's current Cash Flow from Financing is ₹841 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Parenteral's stock overvalued right now?
Sai Parenteral's (NSE:SAIPARENT) has a current Cash Flow from Financing of ₹841 Mil. The current Cash Flow from Financing is ₹841 Mil. Sai Parenteral's' overall GF Score™ is 14/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Sai Parenteral's (NSE:SAIPARENT), the current Cash Flow from Financing is ₹841 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sai Parenteral's Ltd is a diversified pharmaceutical formulations company. Its business is organised in two verticals: (i) Branded Generic Formulations: Through the branded generics portfolio, it serves the domestic market with formulations across multiple therapeutic areas. and (ii) Contract Development and Manufacturing Organisation (CDMO): It provides CDMO services to pharmaceutical companies, supporting activities from product development to commercial manufacturing. Its product portfolio includes cardiovascular care, neuropsychiatry, anti-diabetic therapy, respiratory health, antibiotics, gastroenterology, vitamins, etc. The majority of the company's revenue is derived from the Branded Generic Formulations business.
14GF Score
Get the complete analysis for NSE:SAIPARENT
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SAIPARENT has been successfully added to your 
